The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria

• Status: Unknown status
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multicenter, prospective, interventional study. It does not have a control group. All participants will receive 160 mg valsartan for 8 weeks. Among them, the patients with persistent proteinuria (defined as proteinuria more than 1 g/g after 8 weeks treatment of valsartan) will receive 320 mg valsartan for further 16 weeks. Participants who did not receive any ACEI or ARB previously will have a titration period for 4 weeks (80 mg for 4 weeks, 160 mg for 4 weeks, and then 320 mg for 16 weeks).

The investigators will evaluate the change of urinary angiotensinogen excretion between at baseline, at 8 weeks, and 24 weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Angiotensin II; Angiotensinogen; Valsartan

Criteria

Inclusion Criteria:

• Chronic kidney disease patients with

• proteinuria of 1 - 10 g/day,

• stable and controlled blood pressure (100/60 mmHg - 160/100 mmHg),

• stable renal function with GFR ≥ 30 mL/min/ m2,

• diabetes or non-diabetes

Exclusion Criteria:

• Uncontrolled diabetes (defined as HbA1c > 9.0%)

• Immunosuppressive treatment within 6 months

• Intractable edema

• Hyperkalemia (>5.5 mEq/L) or Hypokalemia (< 3.5 mEq/L)